# CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

> **NCT03721757** · PHASE2 · COMPLETED · sponsor: **The Clatterbridge Cancer Centre NHS Foundation Trust** · enrollment: 21 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Oral Cavity

## Interventions

- **BIOLOGICAL:** Nivolumab, Surgery, Radiotherapy
- **BIOLOGICAL:** Nivolumab, Surgery, Chemoradiotherapy

## Key facts

- **NCT ID:** NCT03721757
- **Lead sponsor:** The Clatterbridge Cancer Centre NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-10
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721757, "CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03721757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*